MRK Merck & Co Inc
- Stocks
- Healthcare
- NYSE: MRK
Price (delayed)
$80.3
Market cap
$200.57B
P/E Ratio
12.35
Dividend/share
$3.2
EPS
$6.5
Enterprise value
$227.97B
Merck & Co., Inc., d.b.a. Merck Sharp & Dohme outside the United States and Canada, is an American multinational pharmaceutical company and one of the largest pharmaceutical companies in the
Highlights
The P/E is 82% lower than the 5-year quarterly average of 69.8 and 22% lower than the last 4 quarters average of 15.9
Merck's equity has increased by 12% YoY
The EPS has grown by 20% YoY but it has contracted by 6% from the previous quarter
The net income is up by 19% year-on-year but it has declined by 6% since the previous quarter
MRK's quick ratio is down by 10% year-on-year
Key stats
What are the main financial stats of MRK
Market
Valuations
Earnings
Shares outstanding
2.5B
Market cap
$200.57B
Enterprise value
$227.97B
Price to earnings (P/E)
12.35
Price to book (P/B)
4.12
Price to sales (P/S)
3.17
EV/EBIT
11.16
EV/EBITDA
9.11
EV/Sales
3.58
Revenue
$63.62B
Gross profit
$48.73B
Operating income
$19.09B
Net income
$16.41B
EBIT
$20.43B
EBITDA
$25.03B
Free cash flow
$14.72B
Per share
Balance sheet
Liquidity
EPS
$6.5
EPS diluted
$6.49
Free cash flow per share
$5.87
Book value per share
$19.51
Revenue per share
$25.35
TBVPS
$32.17
Total assets
$117.52B
Total liabilities
$68.46B
Debt
$35.4B
Equity
$48.99B
Working capital
$11.03B
Debt to equity
0.72
Current ratio
1.42
Quick ratio
0.79
Net debt/EBITDA
1.09
Margins
Efficiency
Dividend
EBITDA margin
39.3%
Gross margin
76.6%
Net margin
25.8%
Operating margin
30%
Return on assets
14%
Return on equity
34.9%
Return on invested capital
26.5%
Return on capital employed
22.3%
Return on sales
32.1%
Dividend yield
3.99%
DPS
$3.2
Payout ratio
49.2%
MRK stock price
How has the Merck stock price performed over time
Intraday
0.34%
1 week
-0.61%
1 month
-3.67%
1 year
-29.24%
YTD
-19.28%
QTD
1.44%
Financial performance
How have Merck's revenue and profit performed over time
Revenue
$63.62B
Gross profit
$48.73B
Operating income
$19.09B
Net income
$16.41B
Gross margin
76.6%
Net margin
25.8%
Merck's operating income has increased by 23% YoY but it has decreased by 5% from the previous quarter
Merck's operating margin has increased by 21% YoY but it has decreased by 4.8% QoQ
The net income is up by 19% year-on-year but it has declined by 6% since the previous quarter
MRK's net margin is up by 17% year-on-year but it is down by 5% since the previous quarter
Price vs fundamentals
How does MRK's price correlate with its fundamentals
Growth
What is Merck's growth rate over time
Valuation
What is Merck stock price valuation
P/E
12.35
P/B
4.12
P/S
3.17
EV/EBIT
11.16
EV/EBITDA
9.11
EV/Sales
3.58
The P/E is 82% lower than the 5-year quarterly average of 69.8 and 22% lower than the last 4 quarters average of 15.9
The EPS has grown by 20% YoY but it has contracted by 6% from the previous quarter
The price to book (P/B) is 34% lower than the 5-year quarterly average of 6.2 and 21% lower than the last 4 quarters average of 5.2
Merck's equity has increased by 12% YoY
MRK's P/S is 28% below its 5-year quarterly average of 4.4 and 17% below its last 4 quarters average of 3.8
Efficiency
How efficient is Merck business performance
The ROS has grown by 22% YoY but it has contracted by 4.2% from the previous quarter
The ROIC rose by 15% YoY but it fell by 7% QoQ
The company's return on assets rose by 10% YoY but it fell by 7% QoQ
Merck's ROE has decreased by 9% from the previous quarter but it has increased by 3.3% YoY
Dividends
What is MRK's dividend history
DPS
$3.2
Dividend yield
3.99%
Payout ratio
49.2%
Recent dividends
Special dividends are included in TTM DPS and yield
Financial health
How did Merck financials performed over time
The total assets is 72% more than the total liabilities
MRK's quick ratio is down by 10% year-on-year
The total assets has grown by 4.3% YoY and by 2.1% from the previous quarter
MRK's debt is 28% smaller than its equity
The debt to equity has contracted by 17% YoY
Merck's equity has increased by 12% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.